Mary Coday, MD
Ophthalmology · Bellevue, WANPI 1689673238
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,643 of the $10,180 with a category attached, or 65.3%. 28 manufacturers reported payments, led by Amgen at 29.8% of the total. Reporting peaked in 2020 at $3,103 and has fallen 50.2% since, to $1,546 in 2025. Among ophthalmology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 223 payments — averaging $45.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- Alcon$2K
- Johnson & Johnson Surgical Vision, Inc.$734
- Johnson & Johnson Vision Care, Inc.$665
- AbbVie$624
- Sun Pharmaceutical Industries Inc.$478
- plus $3K from 22 others
What the payments were for
- Speaking & faculty fees$2,65026%
- Travel & lodging$8578%
- Food & beverage$6,64365%
- Entertainment$300%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 15 | $3,035 |
| Alcon | 29 | $1,863 |
| Johnson & Johnson Surgical Vision, Inc. | 10 | $734 |
| Johnson & Johnson Vision Care, Inc. | 22 | $665 |
| AbbVie(2 entities) | 39 | $624 |
| Sun Pharmaceutical Industries Inc. | 16 | $478 |
| Bausch & Lomb Americas Inc. | 15 | $362 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 13 | $326 |
| Mallinckrodt Hospital Products Inc. | 12 | $293 |
| Lumenis BE Inc | 1 | $212 |
| Rxsight Inc | 5 | $206 |
| Carl Zeiss Meditec USA, Inc. | 1 | $186 |
| Maculogix, Inc. | 3 | $184 |
| Aerie Pharmaceuticals, Inc. | 4 | $166 |
| Dompe US, Inc. | 5 | $136 |
| Glaukos Corporation | 4 | $100 |
| Kala Pharmaceuticals, Inc. | 5 | $96 |
| Oyster Point Pharma, Inc. | 3 | $92 |
| Novartis | 4 | $68 |
| Sight Sciences, Inc. | 3 | $68 |
| Akorn, Inc. | 2 | $48 |
| Optos, Inc. | 3 | $47 |
| Mallinckrodt Enterprises LLC | 2 | $38 |
| Thea Pharma Inc. | 2 | $38 |
| Tarsus Pharmaceuticals, Inc. | 2 | $32 |
| Apellis Pharmaceuticals, Inc. | 1 | $30 |
| Shire North American Group Inc | 1 | $27 |
| Coopervision Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$2,775
- Tecnis 1-piece IOL$538
- Tecnis Multifocal Family of 1-piece IOLS$538
- Tecnis Symfony IOL$538
- Clareon$377
- CEQUA$239
- Acuvue$230
- optilight$212
- CIRRUS HD-OCT$186
- Clareon PanOptix Pro$150
- ARGOS$150
- Rhopressa$125
- Rocklatan$125
- BIOTRUE ONE DAY$125
How this compares
$10,180 in reported general payments places this provider in the 90th percentile of 428 ophthalmology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 86 | $103,725 |
| LumiganBimatoprost | 73 | $50,615 |
| VyzultaLatanoprostene Bunod | 44 | $26,852 |
| XiidraLifitegrast | 27 | $24,372 |
| RocklatanNetarsudil Mesylat/Latanoprost | 52 | $22,593 |
| CombiganBrimonidine Tartrate/Timolol | 30 | $10,108 |
| Latanoprost | 561 | $6,638 |
| RhopressaNetarsudil Mesylate | 13 | $6,520 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 13 | $4,930 |
| Prednisolone Acetate | 70 | $3,491 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 22 | $2,428 |
| Brimonidine Tartrate | 34 | $2,294 |
| Timolol Maleate | 220 | $1,835 |
| Ketorolac Tromethamine | 37 | $1,466 |
| Travoprost | 12 | $1,305 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $624 | $164,449189 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $362 | $51,22471 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $166 | $29,11365 claims |
| AlconSimbrinza | $1,863 | $4,93013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 428 ophthalmology providers in Washington.
Other ophthalmology in Bellevue
- Audrey RostovBellevue$155K
- David SapersteinBellevue$54K
- Howard BarnebeyBellevue$53K
- Stephanie HsuBellevue$6K
- Laura PerimanSeattle$1.7M
- Sheldon CowenSeattle$560K
- Todd SchneidermanSilverdale$200K
- Jennifer ChaoSeattle$188K
- Mark KontosSpokane Valley$175K
- John SamplesOlympia$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.